Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Absci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced two strategic hires joining ...
Absci Corporation ("Absci"), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced today that...
AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the acquisition of Totient, ...
AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a $125 million...
AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity...
AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced that...
AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced the...
AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean ...
AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing and discovery of...
AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of next-generation...
AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of...
AbSci, the Protein Printing™ company, is pleased to announce the appointment of Greg Schiffman, CPA as Chief Financial Officer. Mr. Schiffman is a...
AbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today ...
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced the unveiling of their 12-week cell line...
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi. Under the terms of...
AbSci announced today the appointment of Andrew J.S. Jones, D. Phil. to AbSci's Scientific Advisory Board. Dr. Jones currently serves on the...
AbSci, a global leader in biomanufacturing technologies, today announced the completion of an over-subscribed $12 million Series C financing. As a...
AbSci, announced the addition of Coherus Biosciences' (NASDAQ: CHRS) Chief Scientific Officer, Alan Herman, PhD to its Scientific Advisory Board. Dr. ...
AbSci announced today the appointment of William "Bill" F. Bennett, PhD to AbSci's Scientific Advisory Board. A pioneer of the biotech industry, Dr....
AbSci announced today the appointment of Fred Larimore, PhD to AbSci's Scientific Advisory Board. Dr. Larimore brings over 30 years of experience in...
AbSci announced today that the company has finalized a lease agreement to relocate its headquarters to the new Hudson Building in downtown Vancouver, ...
AbSci announced today the appointment of Daniel Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has served in senior management roles at several...
AbSci announced today the appointment of V. Bryan Lawlis, Ph.D. to AbSci's Board of Directors. Dr. Lawlis has been the CEO and founder of numerous...
AbSci, a global leader in soluble microbial protein expression has secured $5.1M in Series A financing led by Phoenix Venture Partners (PVP). Funding ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.